If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

California legislators have pulled Medicaid coverage for pricey weight loss drugs like Zepbound to patch a $12 billion budget ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...